Markets
Goldman Sachs S&P 500 forecast upgrade crystal ball
(CSA Archive/Getty)

Goldman lifts S&P 500 target on China tariff truce

The blue chips are now less than 5% from retaking all-time highs.

Goldman Sachs analysts are out with a new price target for the S&P 500 (SPDR S&P 500 ETF), citing better-than-expected Q1 earnings results, reacceleration of large-cap tech shares (Invesco QQQ Trust), slightly reduced uncertainty surrounding tariffs and economic growth, and — most importantly — dour sentiment among investors and relatively light positioning.

The team led by Goldman’s David Kostin raised its 12-month forecast for the S&P 500 to 6,500 from 6,200, implying a roughly 10% gain from current prices. That’s slightly less bullish than the Wall Street consensus, which is calling for a gain of about 11% to 6,539.

They wrote:

“Still-light equity investor positioning is the strongest argument for continued near-term market upside. Last Friday, our US Equity Sentiment Indicator registered -1.5 standard deviations, a level that typically indicates above-average S&P 500 returns during the subsequent 2-8 weeks. Hedge fund net leverage and systematic fund equity exposures still register particularly low levels relative to recent history.”

Separately, Goldman analysts also spotlighted the rebound of AI-related stocks as being a key to further upside momentum, particularly what they call “Phase 3” AI shares, which are seeing actual increases to sales right now as a result of the technology, a group that includes Palantir, Amazon, Meta, and Spotify, among others.

More Markets

See all Markets
markets

Spectrum owner Charter Communications is on pace for its worst day ever as broadband numbers and Q1 results disappoint

Cable and broadband company Charter Communications is on pace for its worst-ever trading day on Friday, as investors dump the stock following its Q1 results and forward guidance.

Charter, which owns Spectrum, reported adjusted earnings of $9.17 per share, below Wall Street estimates of $9.96 per share from analysts polled by FactSet. On the company’s earnings call, CFO Jessica Fischer appeared to lower its guidance for full-year revenue per user.

“It’ll be close either way in terms of whether we end up with net growth,” Fischer said.

The company lost 120,000 internet subscribers in the quarter, deeper than the expected 94,800 and double its loss from the same period last year. That news comes one day after Comcast’s earnings provided a bit of optimism for broadband as a category: the company reported Q1 losses of 65,000, significantly improving from 183,000 losses in the same quarter last year. Comcast is down more than 10%, on pace for its worst day since January 2025.

markets

Nvidia poised to snap longest run without a record close since the AI boom began

The stock price of the company responsible for the brains of the AI boom is finally showing some brawn again.

Nvidia, the world’s most valuable company, is poised to close at a record high for the first time since October 29, 2025, on Friday (if it ends above $207.04).

The AI chip trade is on fire, with the Philadelphia Semiconductor Index slated to deliver its 18th consecutive gain as Intel’s robust results and outlook juice the entire ecosystem. Hyperscalers report earnings next week, and their capex guidance can be thought of as the earnings guidance for Nvidia and other AI suppliers for the quarters to come.

This would end Nvidia’s longest stretch without a record close since the unofficial start of the AI boom (when the chip designer delivered blowout quarterly results in May 2023).

(Sorry if I jinx this!)

markets

Lilly slips after prescriptions for its weight-loss pill come in below expectations in second week

Eli Lilly fell on Friday after prescription data for its new weight-loss pill, Foundayo, showed that it’s having a significantly slower rollout than its top competitor.

The pill was prescribed about 3,700 times in its second week, according to IQVIA data cited by Deutsche Bank analysts, compared to the roughly 8,000 they were expecting. Novo Nordisk’s Wegovy pill, which came out in January, hit over 18,000 prescriptions in its second week.

The FDA approved Foundayo on April 1 and shipments began on April 9. Deutsche analysts noted that Lilly’s GLP-1 injections, which currently outsell Novo’s, also had a slower start.

Lilly fell more than 4% after the numbers were released. Novo Nordisk rose more than 5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.